LU91237I2 - Palifermin et ses dérivés pharmaceutiquement acceptables (kepivance) - Google Patents

Palifermin et ses dérivés pharmaceutiquement acceptables (kepivance)

Info

Publication number
LU91237I2
LU91237I2 LU91237C LU91237C LU91237I2 LU 91237 I2 LU91237 I2 LU 91237I2 LU 91237 C LU91237 C LU 91237C LU 91237 C LU91237 C LU 91237C LU 91237 I2 LU91237 I2 LU 91237I2
Authority
LU
Luxembourg
Prior art keywords
cells
protein
kgf
kepivance
palifermin
Prior art date
Application number
LU91237C
Other languages
English (en)
Original Assignee
Rubin Jeffrey S
Finch Paul W
Aaronson Stuart A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23175833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91237(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rubin Jeffrey S, Finch Paul W, Aaronson Stuart A filed Critical Rubin Jeffrey S
Publication of LU91237I2 publication Critical patent/LU91237I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
LU91237C 1989-01-31 2006-04-24 Palifermin et ses dérivés pharmaceutiquement acceptables (kepivance) LU91237I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30428189A 1989-01-31 1989-01-31
PCT/US1990/000418 WO1990008771A1 (fr) 1989-01-31 1990-01-30 Adn codant un facteur de croissance specifique contre des cellules epitheliales

Publications (1)

Publication Number Publication Date
LU91237I2 true LU91237I2 (fr) 2007-02-22

Family

ID=23175833

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91237C LU91237I2 (fr) 1989-01-31 2006-04-24 Palifermin et ses dérivés pharmaceutiquement acceptables (kepivance)

Country Status (22)

Country Link
US (8) US5665870A (fr)
EP (2) EP1016716A3 (fr)
JP (6) JP3298874B2 (fr)
KR (1) KR950012805B1 (fr)
AT (1) ATE197800T1 (fr)
AU (2) AU647732B2 (fr)
CA (2) CA2349875C (fr)
DE (2) DE69033668T2 (fr)
DK (1) DK0555205T3 (fr)
ES (1) ES2153816T3 (fr)
FI (1) FI114711B (fr)
GE (1) GEP20022681B (fr)
HU (1) HU218090B (fr)
IE (1) IE20020188A1 (fr)
LT (1) LT3472B (fr)
LU (1) LU91237I2 (fr)
LV (1) LV10284B (fr)
NL (1) NL300230I2 (fr)
NO (2) NO308312B1 (fr)
RU (1) RU2250213C2 (fr)
SG (1) SG46699A1 (fr)
WO (1) WO1990008771A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008771A1 (fr) 1989-01-31 1990-08-09 Rubin Jeffrey S Adn codant un facteur de croissance specifique contre des cellules epitheliales
GB9203533D0 (en) * 1992-02-19 1992-04-08 Erba Carlo Spa Use of the conjugate between a fibroblast growth factor and a saporin in treating ocular pathologies
US5814605A (en) * 1993-03-26 1998-09-29 Amgen Inc. Therapeutic uses of keratinocyte growth factor
NZ263967A (en) * 1993-03-26 2005-02-25 Amgen Inc Keratinocyte growth factor for treatment of conditions requiring stimulation of epithelial cells, composition and use
DE69434053T2 (de) * 1993-06-29 2006-02-23 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Verkürzter keratinocytenwachstumsfaktor(kgf)mit erhöhter biologischer aktivität
US7084119B2 (en) 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
KR100278597B1 (ko) * 1994-10-13 2001-01-15 스티븐 엠. 오드리 케라티노사이트 성장 인자의 유사체, 이 유사체를 암호하는 핵산 및 그것의 제조방법
US6008328A (en) * 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
PT785950E (pt) * 1994-10-13 2003-09-30 Amgen Inc Analogos do factor de crescimento de queratinocitos
CA2201762C (fr) * 1994-10-13 2001-12-18 Eric W. Hsu Procede pour purifier des facteurs de croissance des keratinocytes
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
ATE274056T1 (de) 1995-10-11 2004-09-15 Chiron Corp Kombination pdgf, kgf, igf und igfbp zur wundheilung
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
DE19716098A1 (de) * 1997-04-17 1998-10-22 Univ Ludwigs Albert Fibroblasten mit einem Fremdgen enthaltende Zusammensetzung zur Behandlung von Wunden
US6228839B1 (en) 1997-12-19 2001-05-08 Emory University Use of keratinocyte growth factor to improve oxidative status
AU1905799A (en) 1997-12-22 1999-07-12 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
CN1295579A (zh) * 1998-02-13 2001-05-16 人类基因组科学公司 角质细胞生长因子2的治疗应用
US6335317B1 (en) 1998-04-10 2002-01-01 Emory University Use of gut-trophic growth factors to improve oxidative status
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US5929051A (en) * 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins
US6313103B1 (en) 1998-05-13 2001-11-06 Carrington Laboratories, Inc. Pectic substance as a growth factor stabilizer
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
US6371984B1 (en) 1999-09-13 2002-04-16 Keraplast Technologies, Ltd. Implantable prosthetic or tissue expanding device
US6783546B2 (en) 1999-09-13 2004-08-31 Keraplast Technologies, Ltd. Implantable prosthetic or tissue expanding device
US6376112B1 (en) 2000-02-11 2002-04-23 General Motors Corporation Controlled shutdown of a fuel cell
US6395414B1 (en) 2000-02-11 2002-05-28 General Motors Corporation Staged venting of fuel cell system during rapid shutdown
US6413662B1 (en) 2000-02-22 2002-07-02 General Motors Corporation Fuel cell system shutdown with anode pressure control
JP2001302691A (ja) * 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆに対する抗体
WO2002077155A2 (fr) * 2001-01-08 2002-10-03 Human Genome Sciences, Inc. Facteur de croissance des keratinocytes-2
WO2002069232A2 (fr) 2001-02-19 2002-09-06 Merck Patent Gmbh Procede d'identification d'epitopes de lymphocytes t et utilisation dans la preparation de molecules a immunogenicite reduite
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
AU2002326742B2 (en) * 2001-08-21 2007-05-31 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
GB0206309D0 (en) * 2002-03-16 2002-05-01 Axordia Ltd Isolated cells
AU2003265612A1 (en) * 2002-08-20 2004-03-11 Curagen Corporation Methods for diagnosing and treatment of conditions that alter phosphate transport in mammals
MX2007006822A (es) 2004-12-15 2007-07-24 Amgen Inc Formulaciones terapeuticas para el factor de crecimiento de queratinocitos.
WO2008005533A2 (fr) * 2006-07-06 2008-01-10 Aaron Thomas Tabor Compositions et procédés de modification génétique de cellules ayant une fonction cosmétique pour l'amélioration de l'aspect cosmétique
WO2008085494A1 (fr) * 2007-01-05 2008-07-17 Helix Biomedix Inc. Peptides bioactifs pour modulation cellulaire et immunologique
US9132202B2 (en) * 2009-07-17 2015-09-15 Aaron T. Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
EP2875359A4 (fr) 2012-03-30 2015-08-19 Charles R Drew University Of Medicine And Science Compositions et procédés de traitement ou de prévention de troubles du syndrome métabolique
KR102277147B1 (ko) * 2017-12-13 2021-07-13 건국대학교 산학협력단 섬유아 성장인자 유래 펩타이드의 골 또는 연골 분화 촉진 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096825A (en) * 1983-01-12 1992-03-17 Chiron Corporation Gene for human epidermal growth factor and synthesis and expression thereof
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
US4473679A (en) 1983-12-12 1984-09-25 Borg-Warner Chemicals, Inc. Thermoplastic acrylic elastomers
US4743679A (en) * 1986-02-24 1988-05-10 Creative Biomolecules, Inc. Process for producing human epidermal growth factor and analogs thereof
US4868113A (en) 1986-03-03 1989-09-19 Rorer Biotechnology, Inc. Recombinant DNA vector encoding human endothelial cell growth factor
US4983679A (en) 1986-05-29 1991-01-08 E. I. Dupont De Nemours And Company β-(keto or sulfonyl)esters from reaction of silylketene acetal and acyl or sulfonyl compound
JP2846385B2 (ja) 1988-03-17 1999-01-13 ノボ・ノルデイスク エー／エス ヘパリン結合タンパク、それらをコードするｄｎａ、それらの製造方法およびそれらを含有する治療用調製品
WO1990008771A1 (fr) 1989-01-31 1990-08-09 Rubin Jeffrey S Adn codant un facteur de croissance specifique contre des cellules epitheliales
DE69434053T2 (de) 1993-06-29 2006-02-23 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Verkürzter keratinocytenwachstumsfaktor(kgf)mit erhöhter biologischer aktivität
KR100278597B1 (ko) 1994-10-13 2001-01-15 스티븐 엠. 오드리 케라티노사이트 성장 인자의 유사체, 이 유사체를 암호하는 핵산 및 그것의 제조방법

Also Published As

Publication number Publication date
GEP20022681B (en) 2002-04-25
DE69033668T2 (de) 2001-04-12
US5654405A (en) 1997-08-05
US5665870A (en) 1997-09-09
JP2001157594A (ja) 2001-06-12
FI913637A0 (fi) 1991-07-30
JP3298874B2 (ja) 2002-07-08
KR910700257A (ko) 1991-03-14
DE122006000021I1 (de) 2006-07-13
AU684278B2 (en) 1997-12-11
LTIP667A (en) 1995-01-31
EP0555205A4 (fr) 1992-06-02
NO972259D0 (no) 1997-05-16
LV10284B (en) 1995-04-20
US5741642A (en) 1998-04-21
NL300230I1 (nl) 2006-07-03
LV10284A (lv) 1994-10-20
JPH04504415A (ja) 1992-08-06
CA2349875C (fr) 2010-02-09
JP2716416B2 (ja) 1998-02-18
JP2006149407A (ja) 2006-06-15
EP1016716A2 (fr) 2000-07-05
AU647732B2 (en) 1994-03-31
DE69033668D1 (de) 2001-01-04
RU2250213C2 (ru) 2005-04-20
NL300230I2 (nl) 2006-09-01
SG46699A1 (en) 1998-02-20
KR950012805B1 (en) 1995-10-21
JPH10243800A (ja) 1998-09-14
NO972259L (no) 1997-05-16
JP2000102396A (ja) 2000-04-11
JP3088983B2 (ja) 2000-09-18
AU6598694A (en) 1994-09-08
NO308312B1 (no) 2000-08-28
NO972617D0 (no) 1997-06-06
AU5049690A (en) 1990-08-24
US6709842B1 (en) 2004-03-23
NO972617L (no) 1997-06-06
IE20020188A1 (en) 2002-06-26
WO1990008771A1 (fr) 1990-08-09
NO308310B1 (no) 2000-08-28
FI114711B (fi) 2004-12-15
EP0555205B1 (fr) 2000-11-29
ES2153816T3 (es) 2001-03-16
JP3802329B2 (ja) 2006-07-26
DK0555205T3 (da) 2001-03-05
CA2038398A1 (fr) 1992-09-16
HUT58759A (en) 1992-03-30
JPH08277227A (ja) 1996-10-22
US6833132B1 (en) 2004-12-21
EP0555205A1 (fr) 1993-08-18
JP3802292B2 (ja) 2006-07-26
CA2038398C (fr) 2002-01-22
US5731170A (en) 1998-03-24
US5707805A (en) 1998-01-13
ATE197800T1 (de) 2000-12-15
EP1016716A3 (fr) 2000-07-12
US6420531B1 (en) 2002-07-16
HU218090B (hu) 2000-05-28
CA2349875A1 (fr) 1992-09-16
LT3472B (en) 1995-10-25

Similar Documents

Publication Publication Date Title
LU91237I2 (fr) Palifermin et ses dérivés pharmaceutiquement acceptables (kepivance)
Kusukawa et al. Expression of matrix metalloproteinase-2 related to lymph node metastasis of oral squamous cell carcinoma: a clinicopathologic study
Carnemolla et al. Localization of the cellular‐fibronectin‐specific epitope recognized by the monoclonal antibody IST‐9 using fusion proteins expressed in E. coli
Hashimoto et al. Unstable expression of E‐cadherin adhesion molecules in metastatic ovarian tumor cells
EP0859833A4 (fr) Replicase recombinee du virus de l'hepatite c
Wang et al. Negative regulators of cell growth
Tentori et al. Proliferation and production of IL-2 and B cell stimulatory factor 1/IL-4 in early fetal thymocytes by activation through Thy-1 and CD3.
Kamp et al. Regulation of PDGF and PDGF receptor in cultured dermal papilla cells and follicular keratinocytes of the human hair follicle
FI820075L (fi) Rekombination-dna-medel och foerfarande
Reichert et al. Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression
BR9713450A (pt) Quimiocinas de mamìfero
ATE48142T1 (de) Blutprotein, verfahren zu seiner herstellung, antikoerper gegen dieses protein und dieses protein oder diese antikoerper enthaltende pharmazeutische zubereitungen.
ATE44621T1 (de) Proteinkonjugate von penicillosaeure, ihre herstellung und verwendung.
EP0833948A4 (fr) Gene et proteine specifiques du colon
Ropers et al. Enzyme immunoassay for the measurement of human tenascin-C on the Bayer Immuno 1™ analyzer
Righetti et al. Charge heterogeneity of recombinant pro-urokinase and urinary urokinase, as revealed by isoelectric focusing in immobilized pH gradients
Hirai et al. Structural optimization of pep7, a small peptide extracted from epimorphin, for effective induction of hair follicle anagen
ATE134218T1 (de) Methode zur reinigung rekombinanter t-pa von den ihren entsprechenden wirtszellproteinen
KR910000735B1 (ko) 혈소판 관련 증식 제어물질
Davis et al. Cloning of a chicken gene homologous to the rabbit mono-ADP-ribosyltransferase gene
赵颖旭 et al. Modulation of 17-1A Antigen Expression and Purification of the Antigen
Murakami et al. Partial Characterization of an Unusual 185 kDa Protein Synthesized by Dermal Fibroblasts from Patients with Marfan Syndrome Identification of the Protein as Type IV Collagen
ATE124722T1 (de) Für das plazentaprotein 9 (pp9) kodierende cdna, ihre isolierung und verwendung.